Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00082485 |
The purpose of this study is to assess the efficacy and safety of baclofen for the treatment of cocaine dependence.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders |
Drug: Baclofen Other: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence |
Enrollment: | 160 |
Study Start Date: | June 2004 |
Estimated Study Completion Date: | November 2005 |
Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Baclofen
Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
|
2: Placebo Comparator |
Other: Placebo
Placebo
|
Double-blind, placebo-controlled, parallel design trial of baclofen for the treatment of cocaine dependence
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
San Francisco General Hosptial | |
San Francisco, California, United States, 94110 | |
Torrance Site | |
Torrance, California, United States, 90502 | |
United States, Colorado | |
Denver VA Medical Center | |
Denver, Colorado, United States, 80220 | |
United States, Maryland | |
VA Maryland Healthcare System | |
Baltimore, Maryland, United States, 21201 | |
United States, Pennsylvania | |
U of Penn School of Medicine | |
Philadelphia, Pennsylvania, United States, 19104 6178 | |
United States, Texas | |
South TX VA Health Care System | |
San Antonio, Texas, United States, 78284 4404 | |
United States, Utah | |
Salt Lake City VA Medical Center | |
Salt Lake City, Utah, United States, 84148 | |
United States, Virginia | |
Institute of Resch & Educ Inova Fairfax Hospital | |
Falls Church, Virginia, United States, 22042 3300 |
Principal Investigator: | Liza Gorgon, M.A. | VA Maryland Health Care System |
Responsible Party: | National Institute on Drug Abuse ( Liza Gorgon ) |
Study ID Numbers: | NIDA-CSP-1021-1 |
Study First Received: | May 11, 2004 |
Last Updated: | May 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00082485 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Cocaine-Related Disorders Neurotransmitter Agents Mental Disorders GABA Agonists Muscle Relaxants, Central |
Baclofen Substance-Related Disorders Disorders of Environmental Origin Peripheral Nervous System Agents Cocaine |
Cocaine-Related Disorders Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Baclofen Physiological Effects of Drugs Disorders of Environmental Origin Neuromuscular Agents Pharmacologic Actions |
Mental Disorders Muscle Relaxants, Central Therapeutic Uses GABA Agonists Substance-Related Disorders GABA Agents Peripheral Nervous System Agents Central Nervous System Agents |